PLoS ONE · 2013 · 78 citations · 25 references
MedicineNeurobiologyPharmacologyDrug DiscoveryNeurochemistryNeuropharmacologyCholinergic PharmacologyCholinergic SignalingEnzyme InhibitionNeurodegenerative Disease PharmacotherapyNeurodegenerative DiseasesNeuroprotectionAcetylcholinesterase InhibitorsAcetylcholinesterase TargetsAche InhibitionAmyloid Beta PeptidesC. Elegans Developmental ModelsPharmacological Treatment Of DementiaProlonged ParalysisTransgenic Animals
The limited symptom relief and side effects of current Alzheimer's disease (AD) medications warrant urgent discovery and study of new anti-AD agents. The "cholinergic hypothesis" of AD prompts us to search for plant-derived acetylcholineesterase (AChE) inhibitors such as galanthamine that has been licensed in Europe for AD treatment. We used the unique amyloid β-expressing transgenic C. elegans CL4176, which exhibits paralysis when human Aβ1-42 is induced, to study two natural benzylphenethylamine alkaloids isolated from Lycoris radiata (L' Her.) Herb, galanthamine and haemanthidine, and their synthetic derivatives 1,2-Di-O-acetyllycorine and 1-O-acetyllycorine for their anti-paralysis effects. Our data indicate that these Lycoris compounds effectively delay the paralysis of CL4176 worms upon temperature up-shift, and prolong the lives of these transgenic worms. Lycoris compounds were shown to significantly inhibit the gene expression of ace-1 and ace-2. Additionally, the Lycoris compounds may modulate inflammatory and stress-related gene expressions to combat the Aβ-toxicity in C. elegans.
25
Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation
Hong Wang, Man Yu, Mahendar Ochani et al. · Nature · 2002 · 3.2K citations
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Kwasi G. Mawuenyega, Wendy Sigurdson, Vitaliy Ovod et al. · Science · 2010 · 2.1K citations · Full text
Steven W. Barger, D Hörster, Koichi Furukawa et al. · Proceedings of the National Academy of Sciences · 1995 · 629 citations